<DOC>
	<DOCNO>NCT01845194</DOCNO>
	<brief_summary>This human pharmacokinetic study investigates , whether process drug metabolism transport determine genetic hereditary factor . Therefore , approve drug apply twin metabolism transport process investigate .</brief_summary>
	<brief_title>Repeated Dose Study Investigation Heritability Genetic Influences Drug Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Torsemide</mesh_term>
	<mesh_term>Talinolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Codeine</mesh_term>
	<criteria>Written inform consent obtain prior study entry include informed consent genetic research Both gender ( male female ) Healthy adult age ≥18 &lt; 65 year Body weight subject gender less 50 kg 120 kg . BMI le 18 kg/m² great 33 kg/m² Willingness meet study instruction cooperate study personal No clinically relevant pathological finding investigation Screening visit . Minor deviation laboratory value normal range may accept , judge investigator clinical relevance Female subject include negative serum pregnancy test screen willingness become pregnant entire study period practice reliable method contraception specify respective protocol section . Dizygotic twin include sibling gender , either male female triplet , quadruplet multiplets least two sibling gender Smokers include sibling smoke similar extend ( +/ 10 cigarette per day ) Involvement plan conduct study ( applies staff directly employ study site / department ) Participation clinical study last 30 day use investigational nonregistered drug vaccine study period within 30 day precede first dose study drug Blood , plasma thrombozyte donation last 30 day prior application test drug Age &lt; 18 year &gt; 65 year Known pregnancy lactation period Any relevant pathological finding investigation screen visit include significant abnormality result medicalscreeninglaboratoryanalysis , especially liver kidney relate parameter . Any disease affect liver kidney impairment liver kidneyfunction Any cardiac disease use betablockers caffeine might contraindicate . Bronchogenic asthma require constant drug treatment ( stag 2 4 asthma ) Known Raynaud 's syndrome Any major acute disease fever ( Temp . &gt; 37.5 C ) Any major gastrointestinal disease gastrointestinal disorder expect significantly interfere pharmacokinetics study drug Gastrointestinal surgery may interfere pharmacokinetics study drug ( except appendectomy herniotomy ) Taking medication within 7 day trial follow exception : Single dose mild analgesic ( e.g . aspirin , paracetamol , ibuprofen ) may take except time 6 hour prior take test drug 24 hour take test drug . Oral contraceptive drug use document exclusion criterion . Other medication might allow single case basis consider necessary subject 's safety wellbeing . History alcohol and/or drug addiction and/or abusive use medicament and/or positive drug screen Any finding could compromise safety participant quality studyresults History severe hypersensitivity reaction anaphylaxis If hypersensitivity allergic reaction one IMPs know enrolment possible application concern IMP must allow sibling ( e.g . allergy sulphonamide prohibits specifically application torsemide ) Clinically significant disease judge investigator Body temperature &gt; 37.5°C prior drug application Known infection HIV , Hepatitis B ( HBsAg ) Hepatitis C Inability unwillingness avoid intake alcohol 48h prior 72hours IMP application Pregnancy ( positive pregnancy test screen and/or treatment ) Lactation unreliable contraception female subject childbearing potential Inability unwillingness provide inform consent abide requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>heritability</keyword>
	<keyword>drug membrane transport</keyword>
	<keyword>drug biotransformation</keyword>
</DOC>